



Thursday 2nd Nov 2023

Today's issue of PD

Pharmacy Daily today features three pages of news, including our **Beauty &** Wellness feature, plus a full page from **BioCeuticals** and the November MIMS Update.

APC focus group

THE Australian Pharmacy Council (APC) is again inviting preceptors and supervising pharmacists to provide feedback on the Intern workplace-based assessment tools via a virtual focus group discussion.

The final focus group will be held on Mon 20 Nov 7:30pm to 8:30pm AEDT (Sydney/ Canberra/Melbourne time).

To receive the Zoom details CLICK HERE.

Pharmacists can find out about the workplace-based research project HERE, or to email APC for more information CLICK HERE.

Countdown to APP2024 has started THE curtain raiser to the largest

pharmacy event in the Southern Hemisphere has started, with the official program now available for the Australian Pharmacy Professional Conference and Trade Exhibition (APP2024), HERE.

Delegates can also network with 450 exhibitors and suppliers at the trade exhibition which will be held on the Gold Coast from 14-17 Mar. Past Pharmacy Guild President

and conference convenor Kos Sclavos (pictured) said the program reflects the conference theme. 'Navigating the future together', and will focus on the profession heading towards 8CPA.

APP last year saw a record 6,000 plus attendees (PD 24 Mar), and Sclavos said what makes APP unique is that it "offers a range of education streams to cover all aspects of community pharmacy including business, innovation and leadership, clinical pharmacy/ product updates, rural pharmacy, cultural engagement, harm



minimisation, and an Early Career Pharmacist stream".

"The Opening Plenary will showcase and recognise awards of excellence including The Pharmacy of the Year Award, the MIMS/ Guild Intern of the Year and the Pharmacy Guild of Australia/ Maxigesic Pharmacy Assistant of the Year," Sclavos explained.

"The Alan Russell Oration on Thu afternoon will provide an update on where we are at with 8CPA and Fri morning's State of the Industry Panel is always a highlight.

"I also look forward to hearing from our keynote speakers, 2019 Australian of the Year, Thai cave

rescue diver and anaesthetist. Dr Richard "Harry" Harris and history-making humanitarian, Rabia Siddique," he remarked.

With the 8CPA negotiations planned to be concluded close to APP in Mar 2024, "this is one year you must attend," urged Sclavos.

APP2024 features pre-conference workshops on Wed 13 Mar.

APP2024 also offers delegates an exciting networking and social program including a 'Glowchella' themed Street Party, the everpopular Welcome Reception, a Women's Networking Lunch and a Pharmacy Assistant Networking Lunch with the 2023 Pharmacy Assistant of the Year, Colby Diek. JG

Future together

BIOCEUTICALS has been supporting professionals for over 30 years with evidencebased products, on-call sales support, education and training. See more on page four.

Guccess is seconds away

Every 60 seconds at Priceline Pharmacy there are*:

- 29 makeup products sold
 8 vitamin & supplement products sold
- 12 haircare products sold
 2[^] vaccinations administered
- 4 fragrance products sold
 56[^] scripts dispensed
- 3 lash products sold

Ready to take your business to the next level?

Find out more

*Priceline Pharmacy retail units sales 1 Jul - 31 Dec 2022. ^2022 Priceline Pharmacy data.

a festival of **1/9**/

t 1300 799 220

page 1

Pharmacy Daily



Thursday 2nd Nov 2023 beauty@pharmacydaily.com.au

Editor's choice: magic of witch hazel preps skin for next steps

A LEGACY American personal care brand, Thayers, has been a steady fixture in medicine cabinets for generations - for 175 years to be exact.

Witch hazel, a flowering plant known for its medicinal properties, has become the brand's hero ingredient.

Today, witch hazel is incorporated into its soughtafter alcohol-free toners and astringents, as well as its new facial mists and body bars.

Thayers witch hazel is certified organic and sourced from a family farm in Fairfield County, Connecticut.

The skincare products are not distilled so they contain 195%

ACRYLIQUE Strawberries 'n'

This long coffin-shaped, two-

toned ombré set featuring a cotton

candy pink base and creamy white

The Strawberries 'n' Irish Cream

Other products in the Acrylique

range include, Sparkling Rosé, Pink

Panties, Spiced Cider, and Sparkler.

tips is your go-to for a clean and

ombré set retails for \$44.95.

classic French tip.

polished look.

Irish Cream is a trendy twist on the

more tannins, which are naturally occurring substances found in the bark and skin of some botanicals, including the ingredient witch hazel.

Tannins have mild antioxidant properties and help to balance the skin's pH levels.

Thayers Toners, (RRP: \$14.49), are fast absorbing, provide hydration and prep skin for the next steps in a skincare regimen, which makes your other skincare products work even better. Think of a toner as the all-

important middle step between



cleansing and application of serums or moisturisers. To use a toner, soak a cotton pad in it and swipe it over the face and neck, or even the chest.

Cotton candy look is in | Stuff champions life-changing mental health



A PURPOSE-driven men's grooming brand, Stuff, champions healthy masculinity promising to keep things uncomplicated and simple for men.

The brand states it has good stuff for men's faces, hair, pits, bod and other bits. Stuff is also proud to partner with The Man Cave, a leading preventative mental health and emotional intelligence service for young men.

For every \$1,000 in sales, Stuff sponsors one boy to experience one of The Man Cave's lifechanging mental health programs.

Stuff's SPF 50+ Face Lotion (RRP:\$20) is super lightweight, so customers won't be sweating up a storm, and has vitamins E & B5 to keep skin hydrated with a smell that will get compliments, not wrinkled-up noses.

The products are Australianmade, vegan and cruelty-free, with no nasty ingredients such as parabens and aluminium, and the bottles are made from recycled plastic that can be recycled too.

ANZ artists in Paris



L'ORÉAL Professionnel invited a team of its top 10 Australian and New Zealand artists to execute all hair deliverables for the Paris Fashion Week, headed up by Director and award-winning hairdresser Scott Sloan.

Scott Sloan was well placed to lead the team of artists as Hair Director with experience in fashion, having been a regular fixture at both Mercedes Benz Fashion Week Australia and New York, London & Milan Fashion Week, as well as Hair Director for the Perth Fashion Festival for four years overseeing 25 runway shows.

"It's a super exciting experience. "Directing the show has fulfilled a lifetime dream of mine, and being able to do it with the L'Oréal Professionnel ANZ hair team here in Paris was so inspirational," remarked Sloan.

"For the look, we were really inspired by the collection from the designer Christopher Esber.

"The hair brief was to have a very organic, textured and not manmade feel to the hair.

"We used the L'Oréal Professionnel range to push the organic feel and worked with each of the models' natural texture to enhance and shape the hair," Sloan concluded.

Beauty

Wellness by Pharmacy Daily



email advertising@pharmacydaily.com.au to find out more



Pharmacy Daily



Dispensary Corner

Get your own copy of Pharmacy Daily

CLICK FOR YOUR FREE SUBSCRIPTION



CDC's newest store is devoted to care

REAL-TIME data from Australia's largest online sexual health clinic group, Stigma Health, revealed that age is no barrier to a healthy sex life.

The latest STI testing data proves that 'Dear Ol' Gramps' sex life might be spicier than you think, with a number of patients pushing 80.

And while the largest age group accessing testing is 20-30, the under 20s were given a run for their money with the 60-70 age group very close behind.

James Sneddon, co-founder of Stigma Health shared "at Stigma Health we're in a really unique position to get a daily insight into the comparative sex lives of Aussies, based on which age groups are accessing STI testing - we always have a bit of a smile on our face when we see the 70+ age group coming through in the data".

When it comes to sexually transmitted infections, testing is one of the best ways to help curb infection, however, stigma surrounding STIs as well as access to testing means many people shy away from that awkward doctor moment.

"The sexual antics of older Australians have their own societal taboos to contend with, so it's great to see that access to discreet online services.

"Obtaining a referral for testing is helping this group enjoy this time of their lives safely," Sneddon added.

So, the next time you're thinking about dropping by for a cuppa with Gramps, Sneddon suggests you call ahead first! **THE** Platform Alliance Group (PAG) has celebrated the opening of the newest location for its Chemist Discount Centre (CDC) pharmacy in Melbourne's suburb of Fawkner.

Located on bustling Bonwick Street, the rebranded pharmacy will be vital to providing services to the community, PAG added.

CDC General Manager Theo Gakelos said, "it is a privilege to be able to support the community of Fawkner with the opening of a pharmacy that offers expert advice for any ailment or issue with prices that won't hurt the pocket".

Owner Ahmed Ibrahim (**pictured** L and R) cannot wait to showcase how the discount model offers expert advice at lower prices, providing accessible healthcare solutions during challenging economic times.

Recognise us all

THE Society of Hospital Pharmacists of Australia (SHPA) has highlighted the need for a consistent, collaborative care approach that recognises the capabilities of the entire pharmacy workforce, including pharmacy technicians, in its recommendations to Unleashing the potential of our workforce - Scope of Practice Review.

SHPA President Tom Simpson said, "we have demonstrated the benefits of utilising pharmacy technicians to capture medication history upon hospital admission, reducing the time needed for this task by 25%, considerably freeing up capacity for the doctor and pharmacist to consult with the patient".



Additionally, Ibrahim is devoted to building and developing long-term relationships with the community to provide them with the best of care, PAG commented.

The celebration included a grand opening with discounted offers, and fun for the local community with face painting, goodie bags and finger food from local vendors. *JG*



WIN WITH DERMAL THERAPY!

Dermal Therapy and Pharmacy Daily are giving away a \$50 Prezzee Card every day this week!

Dermal Therapy's new aluminiumfree Sweat Control Roll-on and Spray is a clinical strength, aluminium-free antiperspirant that provides 48 hour sweat protection and delivers odour relief for the face, hands, and body.

COMPETITION QUESTION

True or False - Dermal Therapy's Sweat control range is an Aluminium-free Antiperspirant.

A. True B. False



For your chance to win, send the correct answer to comp@pharmacydaily.com.au To read T&C's, please click here



www.pharmacydaily.com.au Pharmacy Daily is part of the Business Publishing Group family

of publications. *Pharmacy Daily* is Australia's favourite pharmacy industry Editor - Jayamala Gupte Journalists - Adam Bishop, Myles Stedman, Janie Medbury, Matthew Wai Publisher - Bruce Piper Editorial Director - Damian Francis Associate Publisher - Anna Piper info@pharmacydaily.com.au

FDITORIAL

ADVERTISING AND MARKETING Head of Sales & Marketing - Sean Harrigan Business Development - Reynaldo Tahulending Advertising Operations - Nicki Harford advertising@pharmacydaily.com.au

ACCOUNTS

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia PO Box 1010 Epping NSW 1710 Australia Tel: 1300 799 220 (+61 2 8007 6760)

Sign up free at www.pharmacydaily.com.au

Pharmacy Doily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

Pharmacy Daily

publication.

e info@pharmacydaily.com.au

t 1300 799 220

Travel Daily

🐞 CRUISE

Travel & Cruise

Weekly

trave Bulletin

business events news



Supporting healthcare professionals for over 30 years.

Together, we build a community of natural healthcare experts to unlock better health outcomes for your customers.

Confidence in our products

Designed by practitioners, we choose high quality, evidence-based ingredients to produce products of high standards, credibility and care.

Confidence in our team

Our team of sales consultants, practitioner qualified educators and advisory team are on-call so you can reach us when you need us most.

Confidence for you to recommend

Our education and training support gives you the confidence to support your customers in store.

Join us in our commitment to future success in pharmacy. Call us today to find out more.





CUSTOMER SERVICE cs@bioceuticals.com.au 1300 650 455 (ext. 1)





PRODUCT INFO & ADVICE practitionersupport@bioceuticals.com.au 1300 650 455 (ext. 2)

November 2023

New Products

- Andexanet alfa (Andexxa) is a recombinant form of human factor Xa (FXa) protein that has been modified to lack FXa enzymatic activity. The active site serine was substituted with alanine, rendering the molecule unable to cleave and activate prothrombin, and the gamma-carboxyglutamic acid domain was removed to eliminate the ability of the protein to assemble into the prothrombinase complex, thus removing any anti-coagulant effects. It is a specific reversal agent for FXa inhibitors. The predominant mechanism of action is the binding and sequestration of the FXa inhibitor. In addition, andexanet alfa has been observed to bind to, and inhibit tissue factor pathway inhibitor (TFPI). Inhibition of TFPI activity can increase tissue factor-initiated thrombin generation inducing a pro-coagulant effect. Andexxa has provisional approval for adult patients treated with a direct FXa inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Andexxa powder for solution for injection contains andexanet alfa 200 mg per vial and is available in packs of 4.
- Andusomeran (Spikevax XBB.1.5) is formulated in lipid particles, which enable delivery of the nucleoside-modified mRNA into
 host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which
 protects against COVID-19. Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID-19 in individuals 12 years of
 age and older in accordance with official recommendations. Spikevax XBB 1.5 is contraindicated in individuals with known severe
 allergic reactions (e.g., anaphylaxis) to a previous dose of Spikevax (original), Spikevax Bivalent Original/Omicron (BA.1),
 Spikevax Bivalent Original/Omicron BA.4-5. Spikevax XBB.1.5 suspension for injection contains andusomeran 50 mcg per 0.5 mL
 dose and is available in packs of 10 single-dose vials or prefilled syringes.
- **Mavacamten (Camzyos)** is a selective, allosteric, and reversible cardiac myosin inhibitor. Mavacamten modulates the number of myosin heads that can enter power-generating states, thus reducing, (or in hypertrophic cardiomyopathy (HCM) normalizing), the probability of force-producing systolic and residual diastolic crossbridge formation. Mavacamten also shifts the overall myosin population towards an energy sparing, but recruitable, super-relaxed state. Excess cross-bridge formation and dysregulation of the super-relaxed state of myosin are mechanistic hallmarks of HCM, which can result in hypercontractility, impaired relaxation, excess energy consumption, and myocardial wall stress. In HCM patients, myosin inhibition with mavacamten normalizes contractility, reduces dynamic LV outflow tract obstruction, and improves cardiac filling pressures and biomarkers of cardiac stress, improving symptoms and exercise capacity. *Camzyos is indicated for the treatment of adults with symptomatic NYHA class II-III obstructive HCM*. Camzyos is contraindicated in concomitant use with moderate to strong CYP2C19 inhibitors and inducers, strong CYP3A4 inhibitors, and moderate to strong CYP3A4 inducers. Camyzos capsules contain mavacamten 2.5 mg or 5 mg and are available in packs of 28.
- Rimegepant (Nurtec ODT) binds with high affinity to the human calcitonin gene-related peptide (CGRP) receptor and antagonises CGRP receptor function. Multiple lines of clinical evidence point to a role for CGRP in migraine pathophysiology: 1) serum levels of CGRP are elevated during migraine; 2) treatment with anti-migraine drugs returns CGRP levels to normal coincident with pain relief and 3) intravenous CGRP infusion produces lasting pain in non-migraineurs and migraineurs. *Nurtec ODT is indicated for acute treatment of migraine with or without aura in adults and as prophylactic treatment of episodic migraine in adults who have at least 4 migraine attacks per month*. Nurtec ODT orally disintegrating tablets contain rimegepant 75 mg and are available in packs of 2, 4, 8 or 16.

New Presentation

• **Progesterone** (Prolutex) is now available as a solution for injection. *It is indicated in adults for luteal support as part of an Assisted Reproductive Technology treatment program in women who are unable to use or tolerate vaginal preparations, or where there is a need or preference to use an injectable form of progesterone.* Prolutex is contraindicated in undiagnosed vaginal bleeding; known missed abortion or ectopic pregnancy; severe hepatic dysfunction or disease; known or suspected breast or genital tract cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events; porphyria; and in individuals with a history of idiopathic jaundice, severe pruritus or pemphigoid gestationis during pregnancy. Prolutex contains progesterone 25 mg per 1.112 mL vial and is available in packs of 7.

New Indications

- **Ivosidenib** (Tibsovo) is now indicated for the treatment of acute myeloid leukaemia (AML) that carries an IDH1 R132 mutation as monotherapy, or in combination with azacitidine, in newly diagnosed patients who are not eligible to receive intensive induction chemotherapy; or as monotherapy in patients whose AML is relapsed and/or refractory to prior therapy.
- Secukinumab (Cosentyx) is now indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.

New Contraindications

• **Midodrine HCI (Vasodrine)** is now contraindicated in obliterative blood vessel disease of any severity, acute nephritis, hypertrophy of the prostate gland with residual urine volume increased, and vasovagal hypotension.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.